Light detection action: feasibility of ECL for the monitoring of therapeutic dosage toward personalised medicine

Kelly Brown; Lynn Dennany

doi:10.17868/75592

Light detection action: feasibility of ECL for the monitoring of therapeutic dosage toward personalised medicine

Kelly Brown, Lynn Dennany

Research output: Contribution to conference › Poster

3 Downloads (Pure)

Abstract

Electrochemiluminescence (ECL) has a proven track record for the detection of illicit substances, yet little investigation into its application within medical devices has been witnessed to date. The ability to not only detect therapeutic products such as cancer therapies, but monitor these alongside disease biomarkers will provide the prognostic and diagnostic information required by physicians to begin to construct personalised treatment plans. Here we present an initial feasibility study toward the development of a remote ECL sensor for the monitoring of cancer therapy uptake alongside disease biomarkers to facilitate remote and real-time patient monitoring.

Original language	English
Pages	1
DOIs	https://doi.org/10.17868/75592
Publication status	Published - 2 Mar 2021
Event	2021 #RSCPoster Twitter Conference - Virtual Duration: 2 Mar 2021 → 3 Mar 2021 https://www.rsc.org/our-events/rsc-poster/

Conference

Conference	2021 #RSCPoster Twitter Conference
Period	2/03/21 → 3/03/21
Internet address	https://www.rsc.org/our-events/rsc-poster/

Keywords

electrochemiluminescence (ECL)
biomedical analysis
cancer research

Access to Document

10.17868/75592Licence: CC BY-NC-ND 4.0

Brown-Dennany-RSC2021-Light-detection-action-feasibility-of-ECLFinal published version, 307 KBLicence: CC BY-NC-ND 4.0
Brown-Dennany-RSC2021-Light-detection-action-feasibility-of-ECLOther version, 735 KBLicence: CC BY-NC-ND 4.0

Cite this

@conference{2333936100ea40a3b0c15bc89881de55,

title = "Light detection action: feasibility of ECL for the monitoring of therapeutic dosage toward personalised medicine ",

abstract = "Electrochemiluminescence (ECL) has a proven track record for the detection of illicit substances, yet little investigation into its application within medical devices has been witnessed to date. The ability to not only detect therapeutic products such as cancer therapies, but monitor these alongside disease biomarkers will provide the prognostic and diagnostic information required by physicians to begin to construct personalised treatment plans. Here we present an initial feasibility study toward the development of a remote ECL sensor for the monitoring of cancer therapy uptake alongside disease biomarkers to facilitate remote and real-time patient monitoring.",

keywords = "electrochemiluminescence (ECL), biomedical analysis, cancer research",

author = "Kelly Brown and Lynn Dennany",

year = "2021",

month = mar,

day = "2",

doi = "10.17868/75592",

language = "English",

pages = "1",

note = "2021 #RSCPoster Twitter Conference ; Conference date: 02-03-2021 Through 03-03-2021",

url = "https://www.rsc.org/our-events/rsc-poster/",

}

TY - CONF

T1 - Light detection action

T2 - 2021 #RSCPoster Twitter Conference

AU - Brown, Kelly

AU - Dennany, Lynn

PY - 2021/3/2

Y1 - 2021/3/2

N2 - Electrochemiluminescence (ECL) has a proven track record for the detection of illicit substances, yet little investigation into its application within medical devices has been witnessed to date. The ability to not only detect therapeutic products such as cancer therapies, but monitor these alongside disease biomarkers will provide the prognostic and diagnostic information required by physicians to begin to construct personalised treatment plans. Here we present an initial feasibility study toward the development of a remote ECL sensor for the monitoring of cancer therapy uptake alongside disease biomarkers to facilitate remote and real-time patient monitoring.

AB - Electrochemiluminescence (ECL) has a proven track record for the detection of illicit substances, yet little investigation into its application within medical devices has been witnessed to date. The ability to not only detect therapeutic products such as cancer therapies, but monitor these alongside disease biomarkers will provide the prognostic and diagnostic information required by physicians to begin to construct personalised treatment plans. Here we present an initial feasibility study toward the development of a remote ECL sensor for the monitoring of cancer therapy uptake alongside disease biomarkers to facilitate remote and real-time patient monitoring.

KW - electrochemiluminescence (ECL)

KW - biomedical analysis

KW - cancer research

UR - https://www.rsc.org/our-events/rsc-poster/

U2 - 10.17868/75592

DO - 10.17868/75592

M3 - Poster

SP - 1

Y2 - 2 March 2021 through 3 March 2021

ER -

Light detection action: feasibility of ECL for the monitoring of therapeutic dosage toward personalised medicine

Abstract

Conference

Keywords

Access to Document

Other files and links

Fingerprint

Cite this